Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease
Antonia Pagkali,Anastasios Makris,Kalliopi Brofidi,Aris Agouridis,Theodosios Filippatos
DOI: https://doi.org/10.2147/dmso.s397643
2024-01-23
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Antonia Pagkali, 1 Anastasios Makris, 1 Kalliopi Brofidi, 2 Aris P Agouridis, 3, 4 Theodosios D Filippatos 2 1 School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2 Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece; 3 School of Medicine, European University Cyprus, Nicosia, Cyprus; 4 Department of Internal Medicine, German Oncology Center, Limassol, Cyprus Correspondence: Theodosios D Filippatos, Department of Internal Medicine, School of Medicine, University of Crete, Heraklion, Greece, Tel + (30)2810392960, Fax + (30)2810392359, Email Non-Alcoholic Fatty Pancreas disease (NAFPD), characterized by fat accumulation in pancreatic tissue, is an emerging clinical entity. However, the clinical associations, the underlying molecular drivers, and the pathophysiological mechanisms of NAFPD have not yet been characterized in detail. The NAFPD spectrum not only includes infiltration and accumulation of fat within and between pancreatic cells but also involves several inflammatory processes, dysregulation of physiological metabolic pathways, and hormonal defects. A deeper understanding of the underlying molecular mechanisms is key to correlate NAFPD with clinical entities including non-alcoholic fatty liver disease, metabolic syndrome, diabetes mellitus, atherosclerosis, as well as pancreatic cancer and pancreatitis. The aim of this review is to examine the pathophysiological mechanisms of NAFPD and to assess the possible causative/predictive risk factors of NAFPD-related clinical syndromes. Keywords: non-alcoholic fatty pancreas disease, NAFPD, steatotic pancreatic disease, metabolic dysfunction-associated steatotic pancreatic disease, MASPD Pancreatic fat deposition in the absence of excessive alcohol intake, described as non-alcoholic fatty pancreas disease (NAFPD), 1 is an emerging clinical entity. 2 Despite the higher susceptibility to fat deposition of the pancreas compared to the liver, 3,4 the clinical relevance and underlying pathophysiological mechanisms of pancreatic fat infiltration remain unclear in the medical literature. Robertson F. Ogilvie was the first to describe pancreatic fat deposition in obese cadavers, reporting 17% of pancreatic fat storage, as compared to 9% in lean ones. 5 Since then, excessive storage of fat in pancreatic tissue has been described with various terms, including pancreatic lipomatosis, pancreatic steatosis, lipomatous pseudohypertrophy, fatty pancreas, and more. 6,7 Currently, NAFPD is the widely accepted term, and its prevalence varies significantly among populations. 8–11 There are many sophisticated imaging techniques used as diagnostic tools to evaluate the pancreas, with transcutaneous ultrasound being the most common, 10,12 since it is noninvasive, inexpensive, and easily performed. Nonetheless, endoscopic ultrasound (EUS), 10,13 abdominal computed tomography (CT), 14 or magnetic resonance-based techniques including abdominal magnetic resonance imaging (MRI), 15,16 and magnetic resonance spectroscopy (MRS) 17 can be used to quantify pancreatic fat content with accuracy. A direct comparison of these methods has not been performed yet. MRI enables noninvasive assessment of fat content in solid organs, 18 and with the Iterative Decomposition with Echo Asymmetry and Least squares estimation (IDEAL) method, 19 fat and water can be separated for a more precise organ assessment. EUS allows for a closer access to the pancreas; nonetheless, it is invasive and unsuitable for quantification of the entire pancreatic fat content. 10,13 In the general population and in routine medical checkup settings, invasiveness and cost-effectiveness should always be considered before examining the pancreas. As far as physiological values are concerned, the highest limit of normal pancreatic fat is 10 4% when assessed by MRI/MRS. 9 However, a meta-analysis showed that the upper normal limit of pancreatic fat in healthy individuals, who participated in MRI studies, was 6.2%, 20 a threshold that is recommended for future research use. The aim of this review is to explore the pathophysiological mechanisms of NAFPD and its clinical associations, as well as to examine which of these parameters are possible causative or predictive risk factors of NAFPD. NAFPD is the result of several pathophysiological processes that act simultaneously (Figure 1). These processes are generated mainly from excessive deposition of fat on pancreatic cells and include the following; (1) immediate cellular damage due to direct interaction of fatty tissue with pancreatic cells, with subs -Abstract Truncated-
endocrinology & metabolism